94 results about "Plasma cell" patented technology

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This invention relates to the field of medical technology, specifically to a method for preoperative risk assessment and prediction in liver transplant patients with hepatocellular carcinoma, comprising the following steps: Sample collection: selecting plasma samples and corresponding clinicopathological information from liver transplant recipients of hepatocellular carcinoma, and clarifying the inclusion and exclusion criteria for samples; Plasma cell-free DNA extraction and whole-genome sequencing: extracting and quality-controlling cell-free DNA from the plasma samples collected in step S1, constructing a sequencing library, and performing low-coverage whole-genome sequencing. This invention utilizes plasma-extracted cfDNA for whole-genome sequencing, combined with clinical testing information, to construct a preoperative risk assessment and prediction model for postoperative recurrence in liver transplant recipients of hepatocellular carcinoma based on non-invasive testing. This model can be used to predict the probability of recurrence-free survival before liver transplantation. The model derivation cohort integrates clinical records and circulating tumor DNA data for preoperative recurrence risk prediction.

Disclosed are methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells. The methods may relate to stage-specific differentiation from stem cells or stem-cell derived hematopoietic progenitors through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells.

The invention relates to the technical field of immunization. The invention discloses parabacteroides dieldrii and parabacteroides goldsteinii, an application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of an immunopotentiator of a vaccine, and the immunopotentiator of the vaccine, and particularly discloses the parabacteroides dieldrii and the parabacteroides goldsteinii, the application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of the immunopotentiator of the vaccine. The parabacteroides dieldrii and / or the parabacteroides gold can be used as an immunopotentiator, can activate immunity, enhance antibody titer and shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subgroups in a hair growth center.

The present application provides the medical field, and particularly relates to the use of a substance combined with IGF2BP1 or its target point in the preparation of a multiple myeloma diagnosis or treatment product. The present application determines a new IGF2BP1-CDC5L axis in the 1q+MM subgroup, and provides new insights for developing targeted therapeutic drugs for 1q+MM patients. The present application can predict the prognosis of 1q+MM patients by detecting the IGF2BP1-CDC5L mRNA and protein expression levels in CD138+ plasma cells, and provides a new method for developing 1q+MM detection products. Meanwhile, the present application also provides a new target point and a new inhibitor for the clinical treatment of 1q+MM patient subgroup patients.

The application belongs to the technical field of biotechnology, and discloses a nano antibody targeting B cell BCMA and application thereof. The amino acid sequences of the complementarity determining regions CDR1-CDR3 of the nano antibody are selected from SEQ ID NO. 1-12. The nano antibody provided by the application can specifically bind to B cells in human blood, especially activated plasma cells, so as to eliminate B cells producing pathological antibodies. Compared with traditional antibodies, the nano antibody provided by the application has a smaller molecular weight, high stability, low cost, easy expression and high expression amount, and is suitable for large-scale production. The nano antibody is combined with a solid-phase carrier in the application, so that B cells in blood can be targeted and eliminated, the number of B cells in blood of patients can be reduced in a short time, and the antibody level can be reduced, thereby improving the quality of life, reducing complications, and providing a new treatment option for patients who are ineffective or intolerant to traditional treatment.

The invention discloses a method for extracting cell nucleuses from animal tissues, and relates to the technical field of biology. The background technology indicates that cell nucleus extraction is crucial to multidisciplinary research, but a traditional method has the problems of complex operation, time consumption, low purity, easiness in damaging cell nucleuses and the like, and the prior art is still limited although the prior art is improved. The method comprises the following steps: preparing a sample, and taking fresh or cryopreserved animal tissues; homogenizing the tissues, namely putting the tissues into a homogenizer, and homogenizing at a low speed by adding a cracking buffer solution; carrying out cell lysis, and incubating homogenate on ice; centrifugally separating, centrifuging at low temperature and medium speed, taking precipitate, and discarding supernatant; core washing, re-suspending the precipitate in a washing buffer solution, uniformly mixing and filtering; performing core extraction, re-suspending the precipitate in a suspension buffer solution, and lightly and uniformly mixing; purifying and washing, carrying out density gradient centrifugation on the suspension, dyeing with trypan blue, taking a core layer, and washing for subsequent experiments. The nuclear extraction lysis buffer solution has two proportions of LB1 and LB2, different tissues are suitable for different proportions, and an enzyme inhibitor can be added as required. The method can be used for rapidly extracting various animal tissue cell nucleuses, is complete in shape, large in quantity and few in impurities, is suitable for different tissues, and can be applied to downstream experiments such as single cell nucleus sequencing.

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).

The present invention relates to a biomarker for diagnosing pediatric atopic dermatitis and use thereof. As result of comparing immune phenotypes of a healthy control group with those of pediatric atopic dermatitis patients, it has been identified that Th1, Th2, Th17 and Th22 cells or expression of STAT1, CD6 and ALCAM genes are increased or decreased. In addition, in the present invention, it has been identified that the frequencies of monocytes, plasmacytoid dendritic cells, CD4 central memory T cells, and CD4 effector memory T cells are related to the severity of pediatric atopic dermatitis. Therefore, the present invention can ensure an efficient treatment strategy for pediatric atopic dermatitis by accurately diagnosing pediatric atopic dermatitis and the severity thereof.

Provided herein are activated adoptive T-cell compositions targeting plasma cell dyscrasias such as multiple myeloma and methods of treating plasma cell dyscrasias such as multiple myeloma using such compositions. The T-cell compositions of the present disclosure are activated against a select group of antigens associated with multiple myeloma (MMAAs) and, in certain embodiments, in combination with more widely expressed tumor associated antigens (TAAs). In particular, the T-cell compositions of the present disclosure are directed to the MMAAs selected from B-cell maturation antigen (BCMA), X box Protein 1 (XBP1), CS1, and Syndecan-1 (CD138), or a combination thereof. In certain embodiments, the T-cell composition includes T-cells activated to a TAA selected from preferentially expressed antigen of melanoma (PRAME), Survivin, Wilms' Tumor 1 protein (WT1), and melanoma antigen 3 (MAGE-A3), or a combination thereof.

The present disclosure relates in a first aspect to a method for the treatment of chronic fatigue syndrome (CFS) comprising administering to a patient in need thereof a therapeutically effective amount of inhibitory or cytotoxic agent against plasma cells. In a further aspect, the present disclosure relates to a combination of the inhibitory or cytotoxic agent against plasma cells with a B-cell depleting agent or an inhibitor of B-cell activation in the treatment of chronic fatigue syndrome. In addition, a combination of an inhibitory or cytotoxic agent against plasma cells and B-Cell depleting agent or an inhibitor of B-cell activation are described. Said combination may be provided in form of a kit comprising suitably effective dosages of said compounds. Further, the use of the compounds or the combination in the treatment of CFS is described.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

This invention discloses a method for analyzing the distribution of plasmablasts and Treg cells based on tissue section images, belonging to the field of plasmablast and Treg cell distribution analysis technology. The method includes the following steps: labeling plasmablasts and Treg cells in tissue section images; statistically analyzing the distribution ratio of plasmablasts and Treg cells; calculating the mixed parameters of plasmablasts and Treg cells in the tissue section images; obtaining tissue section images with different prognostic effects as sample images and extracting mixed sample parameters; analyzing the correlation between mixed parameters and prognostic effects based on the mixed sample parameters; and determining whether the prognosis of mice is good based on the distribution of plasmablasts and Treg cells and the correlation. This invention addresses the problem that existing plasmablast and Treg cell distribution analysis techniques lack comprehensive and in-depth analysis of the distribution of plasmablasts and Treg cells, leading to biased assessments of prognostic effects.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

The invention provides application of a biomarker in serum detected by a Raman spectrum in preparation of a product for predicting or detecting non-Hodgkin lymphoma, and belongs to the technical field of medical diagnosis. A spectroscopy basis is provided for mass serological detection data of a patient and early identification of the lymphoplasmal cell lymphoma and the diffuse large B-cell lymphoma, and important information is provided for rapid early identification of the lymphoplasmal cell lymphoma and the diffuse large B-cell lymphoma.

The utility model discloses a blood vessel built-in plasma free DNA enrichment device, which comprises a probe body, a clamping groove, an assembly structure and a rubber plug, through the arrangement of the assembly structure, a worker pushes two groups of push plates inwards to enable two groups of movable structures to slide towards the inner side so as to extrude two groups of first springs, so that the two groups of first springs are separated from each other; when the probe body is assembled, the first spring contracts and drives the two limiting structures to move at the same time, after the movable structure moves in place, limiting on the probe body is relieved, the clamping block is separated from the clamping groove, then the probe body can be separated from the assembly structure, and the effect of conveniently disassembling and assembling the probe body and the assembly structure is achieved; through standardized design, replacement of probe bodies with different magnetic bead amounts and probe sizes is facilitated, and mutual replacement of an assembly structure and probe bodies produced by different manufacturers is facilitated.

B-cell maturation antigen (BCMA) is expressed on plasma cells. The present invention provides methods for desensitizing patients in need of a solid organ transplant to anti-HLA antibodies using bispecific antibodies that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing plasma cells. In certain embodiments, the bispecific antibodies of the present invention reduce alloantibody levels and / or reduce calculated panel reactive antibody levels to facilitate solid organ transplantation and / or improve long term graft survival and / or function.

The present invention relates to the method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing mesenchymal stem / stromal cells, endothelial progenitors and primary plasma cells of patient(s) affected by MM. The present invention further relates to the spheroids obtained by said method and the uses thereof.

The application discloses a trispecific antibody combining CD3, CD19 and BCMA and application thereof. The trispecific antibody comprises a first antigen binding domain combining CD3, a second antigen binding domain combining CD19, a third antigen binding domain combining BCMA and a heterodimeric Fc region. The application recruits and activates T cells through the CD3 binding domain, and realizes broad-spectrum recognition and combination of the whole abnormal B cell lineage from early B cells to terminally differentiated plasma cells through the CD19 and BCMA double binding domains, can more thoroughly eliminate pathological B cells, overcomes the antigen escape or drug resistance problems possibly existing in single target treatment by using multiple synergies, and provides a novel antibody drug for diseases such as multiple myeloma, B cell lymphoma and B cell related autoimmune diseases.

The application relates to a multifunctional contrast agent for capturing plasma cell free DNA and a preparation method and application thereof, the preparation method of the multifunctional contrast agent comprises the following steps: S1, activating a contrast agent surface carboxyl; S2, modifying a DNA binding protein on the contrast agent surface; and S3, sealing unreacted sites on the contrast agent surface. Compared with the prior art, the multifunctional contrast agent prepared by the application has good biocompatibility, not only has an imaging examination function, but also can be applied to capturing cell free DNA in circulating blood, and is further applied to tumor detection and tumor prognosis monitoring.

The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy.

The invention relates to a hepatocyte growth-promoting factor preparation and a preparation method thereof, and belongs to the technical field of medicines. In order to solve the problems of low cell disruption efficiency, large polypeptide activity loss and long freeze-drying period in the existing hepatocyte growth-promoting factor preparation process, the invention provides a preparation method of a hepatocyte growth-promoting factor preparation, which comprises the steps of raw material pretreatment, low-temperature plasma cell disruption, compound protective agent compounding and pulse microwave freeze-drying. According to the method, an argon-oxygen mixed low-temperature plasma crushing technology is adopted, and the cell breakage rate of 99.7% can be achieved only in 10 min; a mannitol + proline + trehalose composite protective agent system is adopted, so that the activity index of the polypeptide is increased by 15.4%, and the validity period of the product is prolonged to 24 months; by adopting the process coupling design of plasma rapid crushing and pulse microwave rapid freeze-drying, the total production period is shortened to 12.5 hours from 30-36 hours of the traditional process, and the production efficiency is improved by more than 60%.

The present invention provides a composition for use in applications such as activating plasmacytoid dendritic cells (pDCs), the composition containing Lactobacillus sakei, MG-LAB279 strain (accession number: NITE BP-03645), and / or a bacterial cell component thereof as an active ingredient.

The invention relates to the technical field of biomedical detection, in particular to a multiple myeloma circulating plasma cell flow cytometry method and system, a peripheral blood sample is used for preparing a single-cell suspension, the single-cell suspension is extracted to prepare a to-be-detected tube (TEST tube), the TEST tube is subjected to non-specific site sealing, and the TEST tube is subjected to non-specific site sealing to obtain the multiple myeloma circulating plasma cell flow cytometry method and the multiple myeloma circulating plasma cell flow cytometry system. The method comprises the following steps: taking a TEST tube as a substrate, adding a multi-fluorescent antibody panel containing nano antibodies aiming at BCMA and GPRC5D to perform cell staining operation, performing flow cytometry analysis on the TEST tube to obtain flow cytometry data, and performing gate analysis on the flow cytometry data according to a preset detection analysis strategy to obtain a fluorescence detection result. The number and phenotypic characteristics of circulating plasma cell (CPC) populations are identified and counted, so that circulating plasma cell detection information is generated.

This invention belongs to the field of biotechnology and discloses a plasma cell-free DNA extraction kit, extraction method, and applications. The kit includes magnetic beads, lysis buffer, proteinase K, binding buffer, washing buffer, and elution buffer. The extraction method involves mixing the plasma sample, lysis buffer, proteinase K, binding buffer, and magnetic beads. The lysed plasma cell-free DNA (cfDNA) is incubated with the magnetic beads to form a magnetic bead-cfDNA complex. Under a magnetic field, the complex is washed to remove various impurities, and the plasma cfDNA is obtained after elution. The method of this invention is simple and rapid, with short sample lysis time and stable quality. Replacing isopropanol with anhydrous ethanol during lysis results in high nucleic acid recovery, making it suitable for plasma cfDNA extraction. The purity is suitable for subsequent sequencing and PCR / Q-PCR. The magnetic bead method is beneficial for large-scale use and has significant implications for research and clinical applications.

The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.

The present disclosure provides, in part, a method of treating an autoimmune disease in a subject by reducing the number of pDCs through administration of a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3). The disclosure also generally relates to methods of monitoring the effectiveness of therapy in subjects receiving DT-IL3 for treating an autoimmune disease, and methods of determining continuing treatment of subjects receiving DT-IL3 for treating an autoimmune disease. The disclosure also provides pharmaceutical compositions of DT-IL3 for use in such methods.

The invention relates to the technical field of immune preparations, in particular to application of Forskolin or pharmaceutically acceptable salt thereof in preparation of a vaccine immunopotentiator. Aiming at the defects of vaccine immunomodulators in the prior art, the invention provides a novel method for enhancing the immune effect of a vaccine by using a natural plant extract Forskolin (as an adenylate cyclase activator), the Forskolin can promote high expression of CXCR4 by plasma cells to obviously enhance the homing ability, the residence ability and the service life of the plasma cells, so that the immune effect of the vaccine is enhanced. Therefore, the long-term immune response of the antibody is improved. The Forskolin directly targets the effector cytoplasm cells immunized by the vaccine, so that the potential safety hazard of the traditional technology is avoided, and meanwhile, more lasting and stable immune protection is provided.

The invention relates to the field of biological medicines, and discloses application of an OGG1 micromolecule agonist in preparation of a medicine for treating liver inflammatory diseases. According to the micromolecule TH10785, by activating the beta, delta-lyase activity of DNA repair enzyme OGG1, the oxidized DNA repair capacity is remarkably enhanced, ROS accumulation in liver cells is reduced, NF-kappa B signal channel activation and proinflammatory factor release are inhibited, and therefore liver inflammation and fibrosis are effectively relieved. Meanwhile, the medicine can inhibit the activation of B cells and the formation of plasma cells, finally reduces the generation of autoimmune antibodies, and improves the immune imbalance state of autoimmune hepatitis. The invention provides an innovative treatment strategy based on OGG1 enzyme function amplification, and a new pharmacological approach is provided for treatment of chronic liver diseases and immunological liver injury.

Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.